Physician profile
Ilya Blokh
NPI 1942253414
$220,044.77
in general payments reported to CMS, 2019-2025
70 companies · $34K in 2025
The $34K reported for 2025 was more than what 95% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $4,752 · 2020: $3,862 · 2021: $45K · 2022: $28K · 2023: $65K · 2024: $39K · 2025: $34K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $55K · Honoraria: $38K · Travel and Lodging: $19K · Food and Beverage: $15K · Consulting Fee: $11K · Education: $820.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $54,819.50 |
| Honoraria | $37,931.00 |
| Travel and Lodging | $19,082.20 |
| Food and Beverage | $14,578.10 |
| Consulting Fee | $11,143.00 |
| Education | $819.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $84,144.71 | 2021-2025 | Monoferric, Cosela |
| Beigene USA, INC. | $38,488.75 | 2022-2025 | Brukinsa |
| Sobi, INC | $22,519.35 | 2022-2025 | |
| Beone Medicines USA, INC. | $14,874.59 | 2025 | Brukinsa, Tevimbra |
| Dova Pharmaceuticals | $14,749.29 | 2019-2021 | |
| Shield Therapeutics INC | $6,527.60 | 2022-2025 | Accrufer |
| Astrazeneca Pharmaceuticals LP | $5,166.95 | 2019-2025 | Enhertu, Calquence |
| Incyte Corporation | $4,395.83 | 2019-2025 | Jakafi, Pemazyre, Monjuvi |
| Janssen Biotech, INC. | $4,377.54 | 2019-2025 | Darzalex, Tecvayli, Carvykti |
| Glaxosmithkline, LLC. | $2,973.24 | 2021-2025 | Jemperli, Zejula, Ojjaara |
| E.R. Squibb & Sons, L.L.C. | $2,594.65 | 2019-2025 | Opdivo, Eliquis, Reblozyl |
| Exelixis INC. | $2,528.74 | 2019-2025 | Cabometyx |
| Pfizer INC. | $1,819.24 | 2019-2025 | |
| Karyopharm Therapeutics INC. | $1,751.12 | 2021-2025 | Xpovio |
| Merck Sharp & Dohme LLC | $964.19 | 2019-2024 | Keytruda, Lynparza, Welireg |
Show all 70 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $813.64 | 2019-2025 | |
| Daiichi Sankyo INC. | $784.62 | 2019-2025 | Enhertu |
| Astellas Pharma US INC | $628.22 | 2019-2025 | Xtandi, Padcev |
| Celgene Corporation | $585.63 | 2021-2025 | Pomalyst, Reblozyl, Opdualag |
| Takeda Pharmaceuticals U.S.A., INC. | $573.98 | 2019-2025 | Ninlaro, Iclusig, Alunbrig |
| Genzyme Corporation | $543.59 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $531.08 | 2019-2024 | Ultomiris |
| Regeneron Healthcare Solutions, INC. | $478.75 | 2019-2023 | Libtayo |
| Csl Behring | $462.89 | 2022-2024 | Kcentra |
| Lilly USA, LLC | $429.99 | 2019-2023 | Jaypirca, Retevmo, Verzenio |
| Rigel Pharmaceuticals, INC. | $407.31 | 2019-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Boehringer Ingelheim Pharmaceuticals, INC. | $407.22 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $387.16 | 2019-2025 | |
| Foundation Medicine, INC. | $356.09 | 2019-2021 | |
| Amgen INC. | $328.34 | 2022-2024 | Lumakras, Prolia, Evenity |
| Taiho Oncology, INC. | $318.87 | 2019-2025 | |
| Genentech USA, INC. | $313.75 | 2019 | |
| Puma Biotechnology, INC. | $309.85 | 2019-2025 | |
| Eisai INC. | $291.03 | 2020-2023 | |
| Emd Serono, INC. | $252.29 | 2019-2025 | Tepmetko |
| Mirati Therapeutics, INC. | $220.47 | 2023-2024 | Krazati |
| Stemline Therapeutics INC. | $212.96 | 2023-2025 | Orserdu |
| Myriad Genetic Laboratories, INC. | $212.74 | 2020-2024 | Myrisk, Precisetumor |
| Seagen INC. | $173.24 | 2020-2023 | Padcev, Tukysa |
| Abbvie INC. | $161.74 | 2020-2025 | Linzess |
| Pharmacyclics LLC, An Abbvie Company | $156.69 | 2019-2022 | |
| Pharmaessentia USA Corporation | $147.84 | 2024-2025 | Besremi |
| Shire North American Group INC | $146.90 | 2019 | |
| Clovis Oncology, INC. | $136.92 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $134.91 | 2019-2023 | Amvuttra |
| Lexicon Pharmaceuticals, INC. | $116.27 | 2019 | |
| Array Biopharma INC | $113.20 | 2020-2023 | Alsuma, Mektovi, Lorbrena |
| Gilead Sciences, INC. | $102.39 | 2022-2023 | Trodelvy |
| Agios Pharmaceuticals, INC. | $94.01 | 2023-2025 | Pyrukynd |
| G1 Therapeutics, INC. | $92.59 | 2022-2023 | Cosela |
| Exact Sciences Corporation | $83.67 | 2024 | Cologuard Collection Kit |
| Global Blood Therapeutics, INC. | $71.84 | 2020-2022 | |
| Myovant Sciences INC. | $69.09 | 2021-2022 | |
| Tersera Therapeutics LLC | $50.02 | 2019 | |
| Adc Therapeutics America, INC. | $47.61 | 2022-2023 | |
| Kyowa Kirin, INC. | $46.94 | 2019-2020 | |
| Novocure INC. | $43.00 | 2023-2024 | Optune |
| Jazz Pharmaceuticals INC. | $40.83 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $34.35 | 2021 | |
| Deciphera Pharmaceuticals INC. | $28.51 | 2024 | Qinlock, Tgct |
| Caris Mpi, INC. | $27.08 | 2025 | Mi Cancer Seek |
| Dendreon Pharmaceuticals LLC | $25.64 | 2025 | Provenge |
| Tempus Ai, INC | $24.23 | 2025 | Xt Cdx |
| Adaptive Biotechnologies Corporation | $22.89 | 2023 | Clonoseq |
| Bio Products Laboratory USA, INC. | $22.44 | 2020 | |
| Blue Earth Diagnostics | $22.33 | 2021 | |
| Spectrum Pharmaceuticals INC. | $22.19 | 2024 | Rolvedon |
| Celltrion USA INC. | $20.86 | 2025 | Vegzelma |
| Verastem, INC. | $19.35 | 2019 | |
| Amag Pharmaceuticals, INC. | $18.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$7,420.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ilya Blokh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.